Ultragenyx Pharmaceutical Inc.
RARENASDAQHealthcare● Active
$21.54
$-0.38(-1.71%)
Market Cap$2.1B
P/E Ratio—
52W High$42.37
52W Low$18.29
Ultragenyx Pharmaceutical Inc. (RARE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RARE · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.67B | $0.56B | $0.43B | $0.36B | $0.35B |
| Cost of Revenue | $0.11B | $0.08B | $0.05B | $0.03B | $0.02B |
| Gross Profit | $0.56B | $0.48B | $0.39B | $0.34B | $0.34B |
| Gross Margin %(computed) | 83.80% | 86.30% | 89.59% | 92.21% | 95.44% |
| Operating Expenses | |||||
| R&D Expenses | $0.75B | $0.70B | $0.65B | $0.71B | $0.50B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $1.10B | $1.02B | $0.96B | $0.98B | $0.72B |
| Operating Income | ($0.54B) | ($0.54B) | ($0.57B) | ($0.65B) | ($0.38B) |
| Operating Margin %(computed) | -79.49% | -95.67% | -131.08% | -178.60% | -108.63% |
| Interest Income | $0.03B | $0.04B | $0.03B | $0.01B | $0.00B |
| Interest Expense | $0.06B | $0.06B | $0.07B | $0.04B | $0.03B |
| Income Before Tax | ($0.57B) | ($0.57B) | ($0.61B) | ($0.70B) | ($0.45B) |
| Income Tax Expense | $0.00B | $0.00B | ($0.00B) | $0.01B | $0.00B |
| Net Income | ($0.57B) | ($0.57B) | ($0.61B) | ($0.71B) | ($0.45B) |
| Net Margin %(computed) | -85.44% | -101.60% | -139.70% | -194.71% | -129.20% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| Wtd Avg Shares | 0.10B | 0.09B | 0.07B | 0.07B | 0.07B |
| EBITDA | ($0.50B) | ($0.47B) | ($0.52B) | ($0.64B) | ($0.41B) |
| EBITDA Margin %(computed) | -74.29% | -83.72% | -118.93% | -176.28% | -116.77% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Ultragenyx Pharmaceutical Inc. data
About Ultragenyx Pharmaceutical Inc. (RARE) Income Statement
Ultragenyx Pharmaceutical Inc. (RARE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RARE reported revenue of $0.67B, gross profit of $0.56B (gross margin 83.80%), and net income of ($0.57B) — a net profit margin of -85.44%.
Frequently asked questions
RARE · 4 questionsUltragenyx Pharmaceutical Inc. (RARE) reported revenue of $0.67B for 2025, up 20.1% year-over-year.
RARE revenueRARE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08